Loading...
Loading...
Oculus Innovative
Sciences
OCLS today
announced the issuance of new U.S. patent for the use of Microcyn® Technology
in the prevention and treatment of peritonitis. In this application, Microcyn®
can be delivered to the peritoneal cavity intra-operatively, laproscopically
or transabdominally; and can be administered to peritoneal tissue already
affected by peritonitis or tissue at risk of developing this infection.
Hoji Alimi, founder and president of Oculus said: "The issuance of this U.S.
patent for prevention and treatment of peritonitis strategically dovetails
with our longer-term plan of securing drug approval from the FDA for the
surgical use of Microcyn Technology. This is a significant market in which
current standards simply don't provide patients with optimum protection. We
believe Microcyn Technology will help reduce the incidence of infection, such
as that associated with peritonitis and other abdominal procedures, and as
such, will reduce healthcare costs and improve patient outcomes."
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in